• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

一例严重肺孢子菌肺炎患者采用甲氧苄啶 - 磺胺甲恶唑与卡泊芬净联合治疗

Combination therapy with trimethoprim-sulfamethoxazole and caspofungin in a case of severe pneumocystis pneumonia.

作者信息

Koshy Robin, Chen Thomas

机构信息

Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Department of Infectious Disease, United States.

出版信息

IDCases. 2019 Jan 26;15:e00496. doi: 10.1016/j.idcr.2019.e00496. eCollection 2019.

DOI:10.1016/j.idcr.2019.e00496
PMID:30828545
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6384316/
Abstract

Trimethoprim-sulfamethoxazole (TMP-SMX, co-trimoxazole, or bactrim) has been the standard first-line treatment against Pneumocystis jirovecii pneumonia (PCP) for decades. However, adverse effects and cases of treatment failure have led to a search for alternative agents. We present a case of a 50 year old immune compromised female whose course of PCP did not improve until Caspofungin was added to TMP-SMX.

摘要

几十年来，甲氧苄啶-磺胺甲恶唑（TMP-SMX，复方新诺明或百炎净）一直是治疗耶氏肺孢子菌肺炎（PCP）的标准一线药物。然而，不良反应和治疗失败的病例促使人们寻找替代药物。我们报告一例50岁免疫功能低下的女性病例，其PCP病情在TMP-SMX基础上加用卡泊芬净后才得以改善。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f7d8/6384316/593c03b8c0d3/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f7d8/6384316/27dff7ccdba3/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f7d8/6384316/d8415bc76cf7/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f7d8/6384316/593c03b8c0d3/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f7d8/6384316/27dff7ccdba3/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f7d8/6384316/d8415bc76cf7/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f7d8/6384316/593c03b8c0d3/gr3.jpg

相似文献

1
Combination therapy with trimethoprim-sulfamethoxazole and caspofungin in a case of severe pneumocystis pneumonia.一例严重肺孢子菌肺炎患者采用甲氧苄啶 - 磺胺甲恶唑与卡泊芬净联合治疗
IDCases. 2019 Jan 26;15:e00496. doi: 10.1016/j.idcr.2019.e00496. eCollection 2019.
2
Trimethoprim-Sulfamethoxazole (Bactrim) Dose Optimization in Pneumonia (PCP) Management: A Systematic Review.复方磺胺甲噁唑（复方新诺明）在肺炎（PCP）管理中的剂量优化：系统评价。
Int J Environ Res Public Health. 2022 Feb 28;19(5):2833. doi: 10.3390/ijerph19052833.
3
Treatment of Pneumocystis carinii pneumonia in patients with AIDS.艾滋病患者卡氏肺孢子虫肺炎的治疗
Clin Pharm. 1988 Jul;7(7):514-27.
4
Efficacies of atovaquone, pentamidine, and trimethoprim/sulfamethoxazole for the prevention of Pneumocystis jirovecii pneumonia in patients with connective tissue diseases.阿托伐醌、喷他脒和甲氧苄啶/磺胺甲恶唑对结缔组织病患者预防耶氏肺孢子菌肺炎的疗效。
J Infect Chemother. 2019 May;25(5):351-354. doi: 10.1016/j.jiac.2019.01.005. Epub 2019 Jan 31.
5
Trimethoprim-sulfamethoxazole combined with echinocandins versus trimethoprim-sulfamethoxazole alone for Pneumocystis pneumonia in patients without human immunodeficiency virus infection: A nationwide retrospective cohort study.在无人类免疫缺陷病毒感染的患者中，甲氧苄啶 - 磺胺甲恶唑联合棘白菌素与单用甲氧苄啶 - 磺胺甲恶唑治疗肺孢子菌肺炎的全国性回顾性队列研究。
J Infect Chemother. 2025 Jan;31(1):102489. doi: 10.1016/j.jiac.2024.08.004. Epub 2024 Aug 6.
6
Safety and efficacy of prophylaxis for Pneumocystis jirovecii pneumonia involving trimethoprim-sulfamethoxazole dose reduction in kidney transplantation.肾移植中涉及减少复方磺胺甲噁唑剂量的预防卡氏肺孢子虫肺炎的安全性和有效性。
BMC Infect Dis. 2019 Apr 5;19(1):311. doi: 10.1186/s12879-019-3944-0.
7
A Case of Pneumonia Caused by Pneumocystis jirovecii Resistant to Trimethoprim-Sulfamethoxazole.1例由对复方新诺明耐药的耶氏肺孢子菌引起的肺炎病例
Korean J Parasitol. 2015 Jun;53(3):321-7. doi: 10.3347/kjp.2015.53.3.321. Epub 2015 Jun 30.
8
Effectiveness and safety of lower dose sulfamethoxazole/trimethoprim therapy for Pneumocystis jirovecii pneumonia in patients with systemic rheumatic diseases: A retrospective multicenter study.低剂量磺胺甲恶唑/甲氧苄啶治疗系统性风湿性疾病患者耶氏肺孢子菌肺炎的有效性和安全性：一项回顾性多中心研究。
J Infect Chemother. 2019 Apr;25(4):253-261. doi: 10.1016/j.jiac.2018.11.014. Epub 2019 Jan 12.
9
Therapeutic failure of trimethoprim/sulfamethoxazole in the treatment of Pneumocystis carinii pneumonia.甲氧苄啶/磺胺甲恶唑治疗卡氏肺孢子虫肺炎的治疗失败
Ann Pharmacother. 1999 Apr;33(4):413-5. doi: 10.1345/aph.18225.
10
High Prevalence of Pneumocystis jirovecii Dihydropteroate Synthase Gene Mutations in Patients with a First Episode of Pneumocystis Pneumonia in Santiago, Chile, and Clinical Response to Trimethoprim-Sulfamethoxazole Therapy.智利圣地亚哥首次发作肺孢子菌肺炎患者中耶氏肺孢子菌二氢蝶酸合酶基因突变的高流行率及对甲氧苄啶-磺胺甲恶唑治疗的临床反应
Antimicrob Agents Chemother. 2017 Jan 24;61(2). doi: 10.1128/AAC.01290-16. Print 2017 Feb.

引用本文的文献

1
Discovery of novel targets for important human and plant fungal pathogens via an automated computational pipeline HitList.通过自动化计算流程HitList发现重要人类和植物真菌病原体的新靶点。
PLoS One. 2025 Jun 3;20(6):e0323991. doi: 10.1371/journal.pone.0323991. eCollection 2025.
2
Efficacy of initial caspofungin plus trimethoprim/sulfamethoxazole for severe PCP in patients without human immunodeficiency virus infection.初始卡泊芬净联合复方磺胺甲噁唑治疗人类免疫缺陷病毒阴性重症卡氏肺孢子菌肺炎的疗效。
BMC Infect Dis. 2023 Jun 16;23(1):409. doi: 10.1186/s12879-023-08372-z.
3
Efficacy of Low-Dose Trimethoprim/Sulfamethoxazole for the Treatment of Pneumonia in Deceased Donor Kidney Recipients.

本文引用的文献

1
Efficacy of caspofungin combined with trimethoprim/sulfamethoxazole as first-line therapy to treat non-HIV patients with severe pneumocystis pneumonia.卡泊芬净联合复方磺胺甲恶唑作为一线治疗方案用于治疗非HIV感染的重症肺孢子菌肺炎患者的疗效。
Exp Ther Med. 2018 Feb;15(2):1594-1601. doi: 10.3892/etm.2017.5516. Epub 2017 Nov 16.
2
Successful treatment of severe Pneumocystis pneumonia in an immunosuppressed patient using caspofungin combined with clindamycin: a case report and literature review.卡泊芬净联合克林霉素成功治疗免疫抑制患者的重症肺孢子菌肺炎：一例报告及文献复习
BMC Pulm Med. 2016 Nov 11;16(1):144. doi: 10.1186/s12890-016-0307-0.
3
低剂量甲氧苄啶/磺胺甲恶唑治疗已故供体肾移植受者肺炎的疗效
Infect Drug Resist. 2021 Nov 24;14:4913-4920. doi: 10.2147/IDR.S339622. eCollection 2021.
4
Caspofungin and Pneumonia: It Is Time To Go Ahead.卡泊芬净与肺炎：是时候继续推进了。
Antimicrob Agents Chemother. 2019 Sep 23;63(10). doi: 10.1128/AAC.01296-19. Print 2019 Oct.
Caspofungin salvage therapy in Pneumocystis jirovecii pneumonia.
卡泊芬净挽救治疗耶氏肺孢子菌肺炎
J Microbiol Immunol Infect. 2017 Aug;50(4):547-548. doi: 10.1016/j.jmii.2016.03.008. Epub 2016 Mar 28.
4
Efficacy of caspofungin, a 1,3-β-D-glucan synthase inhibitor, on Pneumocystis carinii pneumonia in rats.1,3-β-D-葡聚糖合酶抑制剂卡泊芬净对大鼠卡氏肺孢子虫肺炎的疗效。
Med Mycol. 2014 Nov;52(8):798-803. doi: 10.1093/mmy/myu060. Epub 2014 Oct 6.
5
Combination of caspofungin and low-dose trimethoprim/sulfamethoxazole for the treatment of severe Pneumocystis jirovecii pneumonia in renal transplant recipients.卡泊芬净联合小剂量复方磺胺甲噁唑治疗肾移植受者重症肺孢子菌肺炎。
Nephrology (Carlton). 2013 Nov;18(11):736-42. doi: 10.1111/nep.12133.
6
Is caspofungin really an effective treatment for Pneumocystis jirovecii pneumonia in immunocompromised patients without human immunodeficiency virus infection? Experiences at a single center and a literature review.卡泊芬净对无人类免疫缺陷病毒感染的免疫功能低下患者的耶氏肺孢子菌肺炎真的是一种有效的治疗方法吗？单中心经验及文献综述。
Scand J Infect Dis. 2013 Jun;45(6):484-8. doi: 10.3109/00365548.2012.760842. Epub 2013 Jan 15.
7
Echinocandin treatment of pneumocystis pneumonia in rodent models depletes cysts leaving trophic burdens that cannot transmit the infection.棘白菌素类药物治疗啮齿动物模型中的肺孢子菌肺炎会耗尽包囊，留下无法传播感染的滋养负荷。
PLoS One. 2010 Jan 29;5(1):e8524. doi: 10.1371/journal.pone.0008524.
8
Clinical significance and phylogenetic relationship of novel Australian Pneumocystis jirovecii genotypes.新型澳大利亚耶氏肺孢子菌基因型的临床意义及系统发育关系
J Clin Microbiol. 2009 Jun;47(6):1818-23. doi: 10.1128/JCM.02102-08. Epub 2009 Apr 15.
9
Pneumocystis jirovecii pneumonia in Spanish HIV-infected patients in the combined antiretroviral therapy era: prevalence of dihydropteroate synthase mutations and prognostic factors of mortality.联合抗逆转录病毒治疗时代西班牙HIV感染患者的耶氏肺孢子菌肺炎：二氢蝶酸合酶突变的患病率及死亡预后因素
Diagn Microbiol Infect Dis. 2008 Sep;62(1):34-43. doi: 10.1016/j.diagmicrobio.2008.04.016. Epub 2008 Jun 12.
10
Genotyping of Pneumocystis jiroveci pneumonia in Italian AIDS patients. Clinical outcome is influenced by dihydropteroate synthase and not by internal transcribed spacer genotype.意大利艾滋病患者中耶氏肺孢子菌肺炎的基因分型。临床结局受二氢蝶酸合酶影响，而非内转录间隔区基因型。
J Acquir Immune Defic Syndr. 2007 Aug 15;45(5):521-8. doi: 10.1097/QAI.0b013e3180decbe2.